Cullinan Oncology

Aug 10, 2023

•

Jun 30, 2023

Cullinan Oncology Q2 2023 Earnings Report

Announced second quarter 2023 financial results and provided a corporate update.

Key Takeaways

Cullinan Oncology reported a cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026. The company also announced the initiation of a Phase 3 study of zipalertinib and presented initial clinical monotherapy data for CLN-619 at ASCO 2023.

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) is open for enrollment.

Initial monotherapy clinical data for CLN-619 was presented at ASCO 2023 Annual Meeting; monotherapy expansion cohorts in endometrial and cervical cancers were initiated.

The first patient was dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL).

Cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026.